Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Megestrol Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 6/20 | 1.00 |
| ▸ | AR | P10275 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.80 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.80 |
| ▸ | USP2 | O75604 | 2/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.80 |
| ▸ | THRB | P10828 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Megestrol Acetate SCHEMBL21281326 | 1.00 | AR (1.00) | ARCYP3A4PGRNR3C1LMNA | |
| Megestrol Acetate SCHEMBL5021332 | 1.00 | AR (1.00) | ARCYP3A4PGRNR3C1LMNA | |
| Megestrol Acetate SCHEMBL13660184 | 1.00 | AR (1.00) | ARCYP3A4PGRNR3C1LMNA | |
| Megestrol Acetate SCHEMBL12998544 | 1.00 | AR (1.00) | ARCYP3A4PGRNR3C1LMNA | |
| Megestrol Acetate SCHEMBL14071675 | 1.00 | AR (1.00) | ARCYP3A4PGRNR3C1LMNA | |
| Megestrol Acetate SCHEMBL745 | 1.00 | AR (1.00) | ARCYP3A4PGRNR3C1LMNA | |
| Megestrol Acetate SCHEMBL8817569 | 1.00 | AR (1.00) | ARCYP3A4PGRNR3C1LMNA | |
| Megestrol Acetate SCHEMBL13941350 | 1.00 | AR (1.00) | ARCYP3A4PGRNR3C1LMNA | |
| Megestrol Acetate SCHEMBL11135443 | 0.99 | AR (0.98) | ARCYP3A4PGRNR3C1LMNA | |
| Megestrol Acetate SCHEMBL10684908 | 0.99 | AR (0.98) | ARCYP3A4PGRNR3C1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2922542-A1 | METHODS AND COMPOSITIONS FOR LOCALLY INCREASING BODY FAT | Topokine Therapeutics, Inc. (US) | 2015-09-30 | — | — | EP | claimed |
| WO-2014081941-A1 | METHODS AND COMPOSITIONS FOR LOCALLY INCREASING BODY FAT | TOPOKINE THERAPEUTICS, INC. (US) | 2014-05-30 | — | — | WO | claimed |
| US-20100226989-A1 | Nanoparticulate megestrol formulations | ELAN PHARMA INTERNATIONAL, LIMITED | 2010-09-09 | — | — | US | claimed |
| EP-1901713-A2 | NANOPARTICULATE MEGESTROL FORMULATIONS | Elan Pharma International Limited (IE) | 2008-03-26 | — | — | EP | claimed |
| WO-2007002315-A2 | NANOPARTICULATE MEGESTROL FORMULATIONS | ELAN PHARMA INTERNATIONAL, LIMITED (IE) | 2007-01-04 | — | — | WO | claimed |
| WO-2023178290-A9 | USE OF COMBINED CD274 COPY NUMBER CHANGES AND TMB TO PREDICT RESPONSE TO IMMUNOTHERAPIES | FOUNDATION MEDICINE, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-4399330-A1 | GENE FUSIONS IN SARCOMA | Foundation Medicine, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20240226082-A1 | COMBINATION THERAPIES FOR TREATING CANCER | TESARO, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240110230-A1 | BIOMARKERS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240093304-A1 | ALK FUSION GENES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2024-03-21 | — | — | US | disclosed |
| WO-2024050437-A2 | METHODS FOR EVALUATING CLONAL TUMOR MUTATIONAL BURDEN | FOUNDATION MEDICINE, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| WO-2024007015-A2 | RET GENE FUSIONS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2007013964-A1 | PYRAZOLO PYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007002315-A2 | NANOPARTICULATE MEGESTROL FORMULATIONS | ELAN PHARMA INTERNATIONAL, LIMITED (IE) | 2007-01-04 | — | — | WO | disclosed |
| US-7101576-B2 | Nanoparticulate megestrol formulations | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2006-09-05 | — | — | US | disclosed |
| US-20050233001-A1 | Nanoparticulate megestrol formulations | ELAN PHARMA INTERNATIONAL LTD. | 2005-10-20 | — | — | US | disclosed |
| US-20050008707-A1 | Nanoparticulate megestrol formulations | ELAN PHARMA INTERNATIONAL LTD. | 2005-01-13 | — | — | US | disclosed |
| EP-1494649-A1 | NANOPARTICULATE MEGESTROL FORMULATIONS | Elan Pharma International, Ltd. (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20030219490-A1 | Nanoparticulate megestrol formulations | ELAN PHARMA INTERNATIONAL LTD. | 2003-11-27 | — | — | US | disclosed |
| WO-2003086354-A1 | NANOPARTICULATE MEGESTROL FORMULATIONS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2003-10-23 | — | — | WO | disclosed |